胎儿先天性膈疝中Smart气管封堵装置的无创移除:单臂开放标签1期研究
本研究为在法国巴黎和比利时鲁汶开展的两项平行单中心、单臂、开放标签首次人体试验,评估Smart-TO气管封堵装置在胎儿先天性膈疝中的安全性。48例患者入组,47例尝试FETO,46例成功置入装置;MRI诱导球囊放气率100%(95%CI 92-100),出生时球囊均位于气道外。研究显示磁共振诱导放气有效且短期安全,可避免第二次宫内操作。
要点
- Smart-TO球囊在强磁场附近可自发放气,MRI诱导放气率100%(95%CI 92-100)。
- 出生时所有婴儿的空球囊均位于气道外,无需第二次宫内干预。
- 14例新生儿死亡均归因于肺发育不良,无严重不良事件与装置相关。
核心结论
- Smart-TO球囊可通过MRI磁场有效诱导放气,并支持短期安全性。
- 该技术消除了先天性膈疝胎儿手术中第二次宫内操作的需要。
研究设计与样本
- 在法国巴黎和比利时鲁汶开展的两项平行单中心、单臂、开放标签1期试验。
- 纳入年龄18岁及以上、单胎妊娠、左侧先天性膈疝伴重度或中度肺发育不良者;鲁汶中心还纳入右侧及双侧先天性膈疝伴重度肺发育不良者。
- 共48例患者入组,47例尝试FETO,46例成功置入Smart-TO装置。
主要发现
- FETO中位孕周为29+2周(28+5-30+1周)。
- 置入后发生1例自发放气和1例不明原因宫内胎儿死亡。
- 放气率为100%(95%CI 92-100),出生时所有婴儿的空球囊均位于气道外。
- 存活者中2例发生气管软化,均在新生儿重症监护出院时症状缓解。
- 14例新生儿死亡均归因于肺发育不良;84例不良事件中5例可能与装置相关,40例严重不良事件中无与Smart-TO装置相关者。
关键数值与推荐
- 球囊置入计划在孕27+0周至31+6周之间进行。
- 球囊放气计划在孕34+0周至34+6周之间(或临床需要时提前)通过暴露于MRI磁场进行,随后超声确认放气。
- 主要终点为球囊放气,巴黎中心将出生时球囊从胎儿气道排出作为共同主要结局。
临床怎么用
- 对于符合条件的先天性膈疝胎儿,可考虑使用Smart-TO装置,通过MRI无创诱导放气,避免第二次宫内操作。
- 置入后需监测自发放气、胎儿死亡及气管软化等不良事件。
局限性
- 单臂、开放标签设计,样本量有限。
- 随访仅至新生儿重症监护出院,长期安全性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One of the drawbacks of fetoscopic endoluminal tracheal occlusion (FETO) for congenital diaphragmatic hernia (CDH) is the need for a second intervention to establish airway patency. In this first-in-human study, we aimed to evaluate a novel tracheal occlusion device (Smart-TO) that spontaneously deflates when in close proximity to a strong magnetic field. METHODS: We conducted two parallel single-centre, single-arm, open-label trials in Paris, France, and Leuven, Belgium. Eligibility criteria included patient age 18 years or more, singleton pregnancy with CDH, and severe or moderate pulmonary hypoplasia in left-sided CDH; in Leuven, eligibility criteria also included severe hypoplasia in right-sided and bilateral CDH. Fetal lung size was assessed by measuring the observed-to-expected lung-to-head ratio by ultrasonography. Data for baseline demographics were self-reported and collected at the screening visit. Insertion of the Smart-TO balloon was scheduled between 27+0 weeks and 31+6 weeks of gestation. Balloon deflation was scheduled between 34+0 weeks and 34+6 weeks (or earlier, if clinically indicated) by exposure to the magnetic field of a MRI machine, and ultrasonography was then done to confirm balloon deflation. The primary endpoint was balloon deflation, with expulsion of the balloon from the fetal airways at birth as a coprimary outcome in the Paris arm of the study. The primary outcome was reported with its 95% CI using the continuity-corrected score method for all patients with the investigational medical device in place at the time of deflation. Safety analysis was conducted for all patients in whom FETO was attempted. These trials are registered with ClinicalTrials.gov (NCT04931212 [Paris]) and NCT05100693 [Leuven]) and have been completed. FINDINGS: Between Aug 4, 2021 and Jan 15, 2024, 48 patients were enrolled. Of these, 47 patients underwent FETO, and the Smart-TO was successfully placed in 46 fetuses. Median gestational age at FETO was 29+2 weeks (28+5-30+1 weeks). After placement, there was one spontaneous balloon deflation and one unexplained intrauterine fetal death. In all other patients, MRI machine-induced balloon deflation was attempted. The deflation rate was 100% (95% CI 92-100). At birth, the empty balloon was outside the airways in all infants. There were two cases of tracheomalacia in survivors, both with symptom resolution by the time of discharge from neonatal intensive care. There were 14 neonatal deaths, all attributed to pulmonary hypoplasia. Five adverse events were considered likely related to the device (of a total of 84), and no serious adverse events (of a total of 40) were related to the Smart-TO device. INTERPRETATION: This study shows effective magnetic resonance-induced deflation of the Smart-TO balloon and supports short-term safety. These findings constitute an important advance in fetal surgery for CDH, eliminating the need for a second intrauterine procedure. FUNDING: Clinical Council for Research and Education (Klinische Onderzoeks-en Opleidingsraad) of the University Hospitals of Leuven and Assistance Publique-Hôpitaux de Paris. Investigational devices (Smart-TO) were provided free of charge to patients and institutions by BS-MTI.
引用
- Russo FM, Sananès N, Letourneau A, et al. Non-invasive removal of the Smart tracheal occlusion device for fetal congenital diaphragmatic hernia: a single-arm, open-label, phase 1 study. Lancet. 2026. PMID: 42335922. doi:10.1016/S0140-6736(26)00664-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。